Esperion Therapeutics to Provide First Quarter 2014 Financial Results

Conference Call and Webcast on Monday, May 12, 2014 at 4:30 p.m. Eastern Time

ANN ARBOR, Mich.--()--Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will host a conference call and webcast to report first quarter 2014 operational and financial results. The webcast will take place on Monday, May 12, 2014 at 4:30 p.m. Eastern Time.

The call can be accessed by dialing (877) 312-7508 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing access code 29900745. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at www.investor.esperion.com/events. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently-available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com.

Contacts

Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com

Sharing

Contacts

Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com